Establishment of xenotransplantation model of human CN-AML with FLT3-ITD mut /NPM1 - In NOD/SCID mice

Journal of Huazhong University of Science and Technology - Medical Science

Volumn 33, Issue 3, 2013, Pages 329-334

  Shang, Zhen ^a   Wang, Jue ^a   Wang, Di ^a   Xiao, Min ^a   Li, Tong Juan ^a   Wang, Na ^a   Huang, Liang ^a   Zhou, Jian Feng ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

acute myeloid leukemia; FLT3 ITD mutation; NOD SCID mice; NPM1 mutation; xenotransplantation model

Indexed keywords

CD135 ANTIGEN; FLT3 PROTEIN, MOUSE; NUCLEAR PROTEIN; NUCLEOPHOSMIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ANIMAL; ARTICLE; CANCER TRANSPLANTATION; DISEASE MODEL; FEMALE; GENETICS; HUMAN; KNOCKOUT MOUSE; MALE; METHODOLOGY; MIDDLE AGED; NONOBESE DIABETIC MOUSE; PATHOLOGY; SCID MOUSE; TUMOR CELL LINE; XENOGRAFT; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; MIDDLE AGED; NEOPLASM TRANSPLANTATION; NUCLEAR PROTEINS; TRANSPLANTATION, HETEROLOGOUS; YOUNG ADULT;

EID: 84879316404     PISSN: 16720733     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11596-013-1119-6     Document Type: Article

References (19)

1. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med, 2004,10(8):789-799
2. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood, 2002,100(5):1532-1542
3. Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med, 2008,358(18):1909-1918
4. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood, 1998,92(7):2322-2333
5. Terpstra W, Prins A, Visser T, et al. Conditions for engraftment of human acute myeloid leukemia (AML) in SCID mice. Leukemia, 1995,9(9):1573-1577
6. Lapidot T, Fajerman Y, Kollet O. Immune-deficient SCID and NOD/SCID mice models as functional assays for studying normal and malignant human hematopoiesis. J Mol Med (Berl), 1997,75(9):664-673
7. Ailles LE, Gerhard B, Kawagoe H, et al. Growth characteristics of acute myelogenous leukemia progenitors that initiate malignant hematopoiesis in nonobese diabetic/severe combined immunodeficient mice. Blood, 1999,94(5):1761-1772
8. Rombouts WJ, Martens AC, Ploemacher RE. Identification of variables determining the engraftment potential of human acute myeloid leukemia in the immunodeficient NOD/SCID human chimera model. Leukemia, 2000,14(5):889-897
9. Cheung AM, Chow HC, Kwong YL, et al. FLT3/internal tandem duplication subclones in acute myeloid leukemia differ in their engraftment potential in NOD/SCID mice. Leuk Res, 2010,34(1):119-122
10. Rocquain J, Carbuccia N, Trouplin V, et al. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer, 2010,10:401
11. Gale RE, Green C, Allen C, et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood, 2008,111(5):2776-2784
12. Levis M, Allebach J, Tse KF, et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood, 2002,99(11):3885-3891
13. Mizuki M, Fenski R, Halfter H, et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood, 2000,96(12):3907-3914
14. Grundler R, Miething C, Thiede C, et al. FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model. Blood, 2005,105(12):4792-4799
15. Pearce DJ, Taussig D, Zibara K, et al. AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. Blood, 2006,107(3):1166-1173
16. Lumkul R, Gorin NC, Malehorn MT, et al. Human AML cells in NOD/SCID mice: engraftment potential and gene expression. Leukemia, 2002,16(9):1818-1826
17. Piloto O, Levis M, Huso D, et al. Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice. Cancer Res, 2005,65(4):1514-1522
18. Levis M, Pham R, Smith BD, et al. In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. Blood, 2004,104(4):1145-1150
19. Lewis ID, McDiarmid LA, Samels LM, et al. Establishment of a reproducible model of chronic-phase chronic myeloid leukemia in NOD/SCID mice using blood-derived mononuclear or CD34+ cells. Blood, 1998,91(2): 630-640